Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
Holding CGEM?
Track your performance easily
CGEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.64 - $30.19
Previous Close$17.24
Volume196.44K
Average Volume (3M)719.63K
Market Cap
$1.02B
Enterprise Value$339.76M
Total Cash (Recent Filing)$662.50M
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 11, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding57,976,641
10 Day Avg. Volume489,571
30 Day Avg. Volume719,625
Standard Deviation0.17
R-Squared0.00107
Alpha-0.00069
Financial Highlights & Ratios
Price to Book (P/B)2.35
Price to Sales (P/S)1963.09
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue485.37
Enterprise Value/Gross Profit679.51
Enterprise Value/Ebitda-1.86
Forecast
1Y Price Target
$32.71Price Target Upside85.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Cullinan Management News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe trial completed enrollment ahead of the prior expectation of full enrollment.
Market OpportunityCullinan projects an over $11 billion market opportunity for moderate/severe patients in the U.S.
Promising TreatmentZipalertinib has breakthrough therapy designation from the FDA for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Bears Say
Development TimelineThe projected development timeline for CLN-619 is extended due to a considerable number of avenues for later-stage development.
Product DevelopmentCGEM announced that they will discontinue development of CLN-418 (B7H4x4-1BB bispecific) following review of Phase 1 data.
Product SafetyThe company announced that they observed dose limiting injection site reactions in dose escalation with the subq formulation, and are transitioning to an IV formulation for continued dose escalation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $7.64 and its highest was $30.19 in the past 12 months.
What is Cullinan Management’s market cap?
Currently, no data Available
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Nov 11, 2024 which is in 53 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Aug 08, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.725 by -$0.025.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -$0.81.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 57,976,643 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.725. Following the earnings report the stock price went down -0.967%.
Which hedge fund is a major shareholder of Cullinan Management?
Among the largest hedge funds holding Cullinan Management’s share is Deerfield Management Company, LP. It holds Cullinan Management’s shares valued at 57M.
---
Cullinan Management Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.71 (85.43% Upside)
$32.71 (85.43% Upside)
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.8%
Last 30 Days ▲ 36.5%
Last 30 Days ▲ 36.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.09%
12-Months-Change
Fundamentals
Return on Equity
-24.60%
Trailing 12-Months
Asset Growth
30.51%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Month Forecast
Average Price Target
$32.71
▲(85.43% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Cabaletta Bio
―
Corvus Pharmaceuticals
―
Foghorn Therapeutics
―
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
13/27 ratings generated profit
1 Year Average Return
+10.88%
reiterated a buy rating 3 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +10.88% per trade.
---